01.02.10 Apogenix GmbH (Heidelberg) has initiated a Phase II proof-of-concept study with its lead compound AGP101 + radiotherapy (vs radiotherapy alone) in 83 patients with Glioblastoma Multiforme (GBM). The clinical trial, which is...
more
01.02.10 Funxional Therapeutics Ltd (Cambridge, UK) has completed the Phase I programme of its anti-inflammatory compound FX125L, which belongs to the therapeutic class of Broad-Spectrum Chemokine Inhibitors (BSCIs). In its second safety...
more
01.02.10 The EMA has finished its review of the benefits and risks of taking Biogen Idec and Elan’s multiple sclerosis drug natalizumab (Tysabri) after 23 (14 EU, thereof 1 death) cases of potentially deadly brain infections with the JC...
more
26.10.09 Dublin/Boston – The risk-benefit ratio of Biogen/Elan’s co-marketed multiple sclerosis antibody drug Tysabri (natalizumab) is to be reviewed by the EU’s regulatory authority EMEA. The EMEA said on Friday that it has observed a...
more
16.10.09 Oxford – British gene therapy specialist Oxford BioMedica plc has reported positive interim results from its ongoing Phase I/II trial of ProSavin, a gene therapy for the treatment of Parkinson's disease. All treated patients have...
more
